EMEA-001095-PIP02-12
Key facts
| Invented name |
Tysabri
|
| Active substance |
natalizumab
|
| Therapeutic area |
Neurology
|
| Decision number |
P/0252/2012
|
| PIP number |
EMEA-001095-PIP02-12
|
| Pharmaceutical form(s) |
Concentrate for solution for infusion
|
| Condition(s) / indication(s) |
Treatment of multiple sclerosis
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Biogen Idec Limited
|
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|
| Compliance procedure number |
EMEA-C-001095-PIP02-12
|
| Compliance opinion date |
16/12/2016
|
| Compliance outcome |
positive
|